Venturi Wealth Management LLC Buys 1,288 Shares of Eli Lilly and Company $LLY

Venturi Wealth Management LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,571 shares of the company’s stock after buying an additional 1,288 shares during the quarter. Venturi Wealth Management LLC’s holdings in Eli Lilly and Company were worth $17,594,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hobbs Wealth Management LLC raised its position in Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock valued at $1,205,000 after purchasing an additional 12 shares during the last quarter. Hixon Zuercher LLC raised its position in Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock valued at $1,477,000 after purchasing an additional 12 shares during the last quarter. O Brien Wealth Partners LLC raised its position in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after purchasing an additional 12 shares during the last quarter. Ascent Capital Management LLC raised its position in Eli Lilly and Company by 2.5% in the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock valued at $409,000 after purchasing an additional 12 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners raised its position in Eli Lilly and Company by 2.7% in the 1st quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company’s stock valued at $407,000 after purchasing an additional 13 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David A. Ricks acquired 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock valued at $2,894,841 over the last quarter. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Down 0.1%

LLY stock opened at $844.30 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The business has a fifty day moving average of $736.97 and a 200-day moving average of $766.03. The company has a market cap of $799.09 billion, a P/E ratio of 55.18, a PEG ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the previous year, the firm earned $3.92 earnings per share. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on LLY shares. HSBC lifted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Guggenheim cut their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Finally, Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $938.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.